ESSA Pharma (EPIX) Proxy Filing summary

Executive summary

• Announced a return of capital distribution totaling $80 million as part of the winding-up process and business discontinuance following a transaction with Xeno Therapeutics, Inc., under which Xeno will acquire all outstanding common shares.

• Distribution of approximately $1.69 per common share is scheduled for August 22, 2025, with the ex-dividend date set for August 25, 2025.

• Nasdaq determined that due to the distribution exceeding 25% of share price, shares will trade with due bills from August 19 to August 25, 2025, assigning the right to receive the distribution.

• Forward-looking statements address the timing and completion of the transaction, required approvals, and potential risks and uncertainties.

Voting matters and shareholder proposals

• Shareholders are urged to read the definitive proxy statement and related documents for important information about the proposed transaction and related matters.

• Proxy solicitation involves directors and executive officers, with details on their interests and security holdings disclosed in the proxy statement.

Board of directors and corporate governance

• Directors and executive officers are participants in the proxy solicitation, with their direct or indirect interests detailed in the proxy statement and annual meeting filings.